Fatty liver study tracks 922 patients to uncover hidden risks
NCT ID NCT07433205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 922 adults with metabolic fatty liver disease (MASLD) for up to 2 years. Researchers tracked changes in liver health and looked for clinical and metabolic factors that predict worsening disease, including liver scarring, serious liver events, heart problems, and death. The goal is to better understand who is at highest risk and improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan University affiliated Chengdu Second People's Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- New drug miricorilant tested for fatty liver disease safety
- Natural compound SAMe tested to block liver cancer in High-Risk patients
- New drug combo targets genetic fatty liver in Mid-Stage trial
- DASH diet shows promise against childhood fatty liver